The Evolution of Triamcinolone Acetonide Therapeutic Use in Retinal Diseases: From Off-Label Intravitreal Injection...

Area of Science:

• Ophthalmology
• Drug Delivery Systems
• Nanotechnology

Background:

• Ophthalmic drug delivery to the posterior eye segment is challenging due to complex ocular anatomy.
• Intravitreal injections are a common method for delivering drugs to the posterior segment.
• Corticosteroids, like triamcinolone acetonide (TA), are widely used for posterior segment diseases.

Purpose of the Study:

• To review the evolution of triamcinolone acetonide (TA) in treating posterior segment eye diseases.
• To explore diverse drug delivery platforms for TA, focusing on nanoparticle-based systems.
• To highlight the potential of novel delivery strategies as alternatives to intravitreal injections.

Main Methods:

• Review of existing literature on triamcinolone acetonide (TA) and its delivery methods.
• Analysis of nanoparticle-based delivery systems, including liposomes.
• Comparison of different platforms for treating posterior segment diseases.

Main Results:

• Intravitreal corticosteroids, including TA, are established treatments for various posterior segment conditions.
• Nanoparticle-based TA delivery systems offer a promising alternative to traditional intravitreal injections.
• Topical liposomal formulations of TA have emerged as a particularly promising strategy.

Conclusions:

• Triamcinolone acetonide (TA) remains a crucial therapeutic agent for posterior segment eye diseases.
• Advancements in nanoparticle technology, especially liposomes, offer improved ophthalmic drug delivery potential.
• Novel delivery platforms may enhance treatment efficacy and patient compliance for posterior segment diseases.